Biology of Bone Cancer Pain

Chapter

Abstract

Bone cancer pain is a complex process with many potential targets for therapeutic intervention. As pain is the most common presenting symptom in patients with skeletal metastases and is directly proportional to the patient’s quality of life, clinical advancements in the treatment of bone cancer pain are of the utmost importance. Research targeting pain-related cytokines, anti-osteoclastic medications, and ion channels has shown significant clinical progress in the treatment of cancer-related bone pain. With continued efforts into these and other therapeutic strategies, we hope to continue to improve the quality of life of those patients suffering with bone cancer pain.

Keywords

Bone cancer Pain Skeletal metastasis Osteoclast Ion channels Denosumab Bisphosphonates 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci. 2006;7(10):797–809.CrossRefPubMedGoogle Scholar
  2. 2.
    Mercadante S, Fulfaro F. Management of painful bone metastases. Curr Opin Oncol. 2007;19(4):308–14.CrossRefPubMedGoogle Scholar
  3. 3.
    Jaggi AS, Jain V, Singh N. Animal models of neuropathic pain. Fundam Clin Pharmacol. 2011;25(1):1–28.CrossRefPubMedGoogle Scholar
  4. 4.
    Mach DB, Rogers SD, Sabino MC, et al. Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience. 2002;113(1):155–66.CrossRefPubMedGoogle Scholar
  5. 5.
    Martin CD, Jimenez-Andrade JM, Ghilardi JR, Mantyh PW. Organization of a unique net-like meshwork of CGRP+ sensory fibers in the mouse periosteum: implications for the generation and maintenance of bone fracture pain. Neurosci Lett. 2007;427(3):148–52.PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    White FA, Jung H, Miller RJ. Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci U S A. 2007;104(51):20151–8.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Yoneda T, Hata K, Nakanishi M, et al. Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain. Bone. 2011;48(1):100–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Jimenez-Andrade JM, Mantyh PW. Sensory and sympathetic nerve fibers undergo sprouting and neuroma formation in the painful arthritic joint of geriatric mice. Arthritis Res Ther. 2012;14(3):R101.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Yasui M, Shiraishi Y, Ozaki N, et al. Nerve growth factor and associated nerve sprouting contribute to local mechanical hyperalgesia in a rat model of bone injury. Eur J Pain. 2012;16(7):953–65.CrossRefPubMedGoogle Scholar
  10. 10.
    Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10(9):895–926.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152(3 Suppl):S2–15.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Schwei MJ, Honore P, Rogers SD, et al. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci. 1999;19(24):10886–97.PubMedGoogle Scholar
  13. 13.
    Sabino MA, Mantyh PW. Pathophysiology of bone cancer pain. J Support Oncol. 2005;3(1):15–24.PubMedGoogle Scholar
  14. 14.
    Schmidt BL, Hamamoto DT, Simone DA, Wilcox GL. Mechanism of cancer pain. Mol Interv. 2010;10(3):164–78.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Jimenez-Andrade JM, Bloom AP, Stake JI, et al. Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain. J Neurosci. 2010;30(44):14649–56.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Yanagisawa Y, Furue H, Kawamata T, et al. Bone cancer induces a unique central sensitization through synaptic changes in a wide area of the spinal cord. Mol Pain. 2010;6:38.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Wang XW, Hu S, Mao-Ying QL, et al. Activation of c-jun N-terminal kinase in spinal cord contributes to breast cancer induced bone pain in rats. Mol Brain. 2012;5:21.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Mantyh WG, Jimenez-Andrade JM, Stake JI, et al. Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain. Neuroscience. 2010;171(2):588–98.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    McKelvey L, Shorten GD, O'Keeffe GW. Nerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management. J Neurochem. 2013;124(3):276–89.CrossRefPubMedGoogle Scholar
  20. 20.
    Sevcik MA, Ghilardi JR, Peters CM, et al. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain. 2005;115(1–2):128–41.CrossRefPubMedGoogle Scholar
  21. 21.
    Warrington RJ, Lewis KE. Natural antibodies against nerve growth factor inhibit in vitro prostate cancer cell metastasis. Cancer Immunol Immunother. 2011;60(2):187–95.CrossRefPubMedGoogle Scholar
  22. 22.
    Jimenez-Andrade JM, Ghilardi JR, Castaneda-Corral G, Kuskowski MA, Mantyh PW. Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain. Pain. 2011;152(11):2564–74.PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Hans G, Deseure K, Adriaensen H. Endothelin-1-induced pain and hyperalgesia: a review of pathophysiology, clinical manifestations and future therapeutic options. Neuropeptides. 2008;42(2):119–32.CrossRefPubMedGoogle Scholar
  24. 24.
    Peters CM, Lindsay TH, Pomonis JD, et al. Endothelin and the tumorigenic component of bone cancer pain. Neuroscience. 2004;126(4):1043–52.CrossRefPubMedGoogle Scholar
  25. 25.
    Hunt SP, Mantyh PW. The molecular dynamics of pain control. Nat Rev Neurosci. 2001;2(2):83–91.CrossRefPubMedGoogle Scholar
  26. 26.
    Patil SB, Brock JH, Colman DR, Huntley GW. Neuropathic pain- and glial derived neurotrophic factor-associated regulation of cadherins in spinal circuits of the dorsal horn. Pain. 2011;152(4):924–35.CrossRefPubMedGoogle Scholar
  27. 27.
    Premkumar LS. Targeting TRPV1 as an alternative approach to narcotic analgesics to treat chronic pain conditions. AAPS J. 2010;12(3):361–70.PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    White JP, Urban L, Nagy I. TRPV1 function in health and disease. Curr Pharm Biotechnol. 2011;12(1):130–44.CrossRefPubMedGoogle Scholar
  29. 29.
    Brown DC, Iadarola MJ, Perkowski SZ, et al. Physiologic and antinociceptive effects of intrathecal resiniferatoxin in a canine bone cancer model. Anesthesiology. 2005;103(5):1052–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Ghilardi JR, Rohrich H, Lindsay TH, et al. Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci. 2005;25(12):3126–31.CrossRefPubMedGoogle Scholar
  31. 31.
    Clohisy DR, Ramnaraine ML. Osteoclasts are required for bone tumors to grow and destroy bone. J Orthop Res. 1998;16(6):660–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Roudier MP, Bain SD, Dougall WC. Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats. Clin Exp Metastasis. 2006;23(3–4):167–75.CrossRefPubMedGoogle Scholar
  33. 33.
    Lamoureux F, Moriceau G, Picarda G, Rousseau J, Trichet V, Redini F. Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment. Biochim Biophys Acta. 2010;1805(1):17–24.PubMedGoogle Scholar
  34. 34.
    Saad F, Mulders P. Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancers. Anticancer Agents Med Chem. 2012;12(2):129–36.CrossRefPubMedGoogle Scholar
  35. 35.
    Diel IJ, Kurth AH, Sittig HB, et al. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study. Support Care Cancer. 2010;18(10):1305–12.CrossRefPubMedGoogle Scholar
  36. 36.
    Saad F, Eastham J. Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology. 2010;76(5):1175–81.CrossRefPubMedGoogle Scholar
  37. 37.
    Broom R, Du H, Clemons M, et al. Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the functional assessment of cancer therapy-bone pain. J Pain Symptom Manage. 2009;38(2):244–57.CrossRefPubMedGoogle Scholar
  38. 38.
    Namazi H. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity: a novel molecular mechanism. J Thorac Oncol. 2008;3(8):943–4.CrossRefPubMedGoogle Scholar
  39. 39.
    Zhu M, Liang R, Pan LH, et al. Zoledronate for metastatic bone disease and pain: a meta-analysis of randomized clinical trials. Pain Med. 2013;14(2):257–64.CrossRefPubMedGoogle Scholar
  40. 40.
    Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–22.PubMedCentralCrossRefPubMedGoogle Scholar
  42. 42.
    Ford JA, Jones R, Elders A, et al. Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis. Eur J Cancer. 2013;49(2):416–30.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Orthopaedic SurgeryUniversity of KentuckyLexingtonUSA
  2. 2.Department of Orthopaedic Surgery and Masonic Cancer CenterUniversity of MinnesotaMinneapolisUSA

Personalised recommendations